Articles On Althea Group Holdings (ASX:AGH)

Althea Group Holdings Ltd (ASX:AGH) has sold its MyAccess Clinics business in the United Kingdom and Ireland to Montu UK Ltd for $1 million as part of a streamlining plan. MyAccess, which manufactures and retails cannabis products, provi...

Althea Group (ASX: AGH) has ramped up its cost cutting drive with an agreement to sell its MyAccess Clinics business in the UK and Ireland to a subsidiary of fellow Melbourne-based medicinal cannabis group Montu for $1 million. Althea laun...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

ASX and regional markets are sharply lower after Wall St tech crunch All 11 local sectors hit, InfoTech smashed hardest on -2.7pc Tissue Repair leads small caps on happy TGA approval news   The benchmark has followed sharp falls across...

Althea’s US subsidiary enters key joint venture to target the legal US cannabis-infused beverages market The market is valued at nearly US$967 million and projected to reach US$19 billion by 2028 Five flavoured beverages have been develop...

Immutep receives FDA feedback for its TACTI-004 Phase III trial design for tackling non small-cell lung cancer Althea forms JV to enter the US cannabis beverage market Chimeric enrols first participant in a Phase 1/2 trial for its CHM CDH1...

Althea Group (ASX:AGH) has inked agreements “to establish [a] joint venture” with Flora Growth Corporation to make cannabis-based beverages. Althea cited figures on Monday claiming the cannabis beverages market is worth just short of USD...

The ASX is set to fall when it opens Monday, following Wall Street’s losses Major tech stocks like Nvidia and CrowdStrike saw drops, while crude oil tumbled 3pc President Biden has ended his re-election bid   The ASX200 index is expected...

The cannabis industry is poised for growth, driven by evolving legalisation globally Investment opportunities therefore exist across the sector We take a look at the ASX weed stock winners over the past month    The cannabis industry is c...

ASX 200 adds about 60 points after intraday record Nine of 11 sectors higher, IT weighed by US megatech losses Pearl Gull Iron pops on REE in Chile   Local markets surged on Friday following positivity overnight on Wall Street after so...

Althea Group launches new medical cannabis dried flowers in Aus and UK GMP-certified range developed with Rocket Factory Company plans to launch more products in the future   Special Report: Althea Group has launched its new medicinal ca...

  Althea navigates shifts in cannabis market by restructuring its operations and aiming for positive EBITDA by FY25 Althea’s subsidiary, Peak, eyes growth in its recreational cannabis business Peak is set to capitalise on the lucrative US...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

ASX drops over 1pc as tech, retail, banks fall; energy resists Bond yields surge, impacting goldies Ethereum ETFs approved, await filings   Energy was the only sector showing some sort of resistance on Friday as the ASX was engulfed in a...

Althea Group Holdings is on a high today, up 11 percent on the ASX on announcing that its Canadian subsidiary, Peak Processing, has joined forces with Flora Growth to introduce cannabis drinks to the US beverages market. The cannabis med...

PYC Therapeutics gets FDA approval PYC Therapeutics (ASX:PYC) has received an Orphan Drug Designation (ODD) from the US FDA for its drug candidate, PYC-001, aimed at treating OPA1-associated vision loss. The ODD is a special designation giv...

ASX 200 set for losses on US market woes and Fed uncertainty Nvidia soars while Boeing falters; Live Nation hit by antitrust worries SpaceX eyes share sale, aiming for $200B valuation   The ASX 200 is poised for sharp losses again when...

So it’s been a dark few years for the brave new world which was cannabis investing. That’s changed suddenly, powerfully with the alignment of two unlikely stars. The first is this:   And the second – even more unlikely, is this:   That’s...

Where are we in terms of US legalisation of cannabis? What about the current legal landscape for cannabis in Australia? We look at the best performing ASX weed stocks this past month   Global weed stocks have been on bumpy ride over the p...

Australian-founded medicinal cannabis company Althea Group (ASX: AGH) has announced staff redundancies that have shaved $1.5 million from its cost base as the first phase of a planned restructure in the wake of a challenging time for the se...

Medicines cannabis company Althea Group Holdings (ASX:AGH) has updated on developments in France’s generalisation of the use of related products.

Material uncertainties have been raised about two of the largest medicinal cannabis companies listed on the ASX to continue as going concerns, after Cann Group (ASX: CAN) and Althea Group (ASX: AGH) incurred December half losses of $14.3 mi...

Cannabis stocks could rise after the removal of US House Speaker Montu says TGA has to allow the term ‘medicinal cannabis’ to be used We look at the best performing ASX weed stocks over the past month   Some experts believe cannabis stock...

Althea’s cannabis oil approved for reimbursement in Ireland Imugene dosed first patient in onCARlytics Phase 1 trial on solid tumours   Althea’s cannabis oil approved for reimbursement Cannabis company Althea Group (ASX:AGH) has announced...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Global Health announces deal with Fujitsu Australia Althea raises $5.32m in sale and leaseback deal Immutep to present data from TACTI-002 in key international forum   Global Health signs with Fujitsu Global Health (ASX:GLH), a provider o...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Stockhead’s Top 10 at shortly-before-11-ish, produced as on-time as humanly possible, despite being handicapped by some decidedly non-human and highly-unfriendly technology. On a slightly-related note, if anyone out there needs parts for an...

Althea extends contract in Canada Clarity moves forward to cohort 3 Cynata opens Phase 2 recruitment   Althea extends deal in Canada for cannabis drinks Cannabis company Althea Group (ASX:AGH) announced that its wholly owned subsidiary, P...

ASX cannabis share Althea Group Holdings Ltd (ASX: AGH) leapt by as much as 27% this morning after the company revealed record quarterly sales of $9.24 million. The company also achieved its maiden monthly operating profit in March, and...

Althea Group (AGH) secures an additional $2.2 million in funding through convertible notes The funding boost comes from US-based institutional investor, Obsidian Global Partners The money will support the launch of AGH’s new SKU’s, an...

Two more US states join the 19 that already allow legal recreational cannabis use ECS Botanics’ Victorian medical cannabis facility is safe from flooding in the state, so far Cann looks to commercialise its Satipharm CBD capsules for over-...

Cannabis-based medicine supplier Althea Group (AGH) receives firm commitments to raise $1.5 million via a share placementThe money will be raised through the issue of 22.4 million new fully-paid ordinary shares to institutional and sophisti...

Althea Group (AGH) enters a trading halt while it plans an upcoming capital raiseIn its September quarterly report, the medicinal cannabis company says the capital raise will “improve its financial position” after a period of increased oper...

It’s time to get cozy and laugh at the lunacy that’s been unfolding here – and abroad – at the intersections of business, entertainment and news, and perilously close to the boundaries of good taste. So let’s kick off our sensible polyester...

ASX 200 rises over 1% on Monday after strong US leads, before Tuesday RBA meeting Small cap index finds nuthin’ as energy, materials fall Up circa 550%, WA1 is still rising   This is happening. Always trust a chartered professional accoun...

Cambridge says cannabis smokers are not actually lazy, that’s a myth USyd wants to test home-grown cannabis in the ACT Incannex joins the big leagues S&P/ASX300 index   It turns out that the lazy stoner stereotype is actually a myth,...

Invion’s lead drug is found to be effective against anal cancer Althea launches new cannabis products Invion (ASX:IVX) surged 17% this morning after telling the market that its lead drug INV043 is effective against anal cancer. A vitro st...

Cannabis-based medicine supplier Althea (AGH) launches two new products to meet patient needsAlthea CBD25 is the company’s exclusive range of soft gel capsules which contain less than 25mg of cannabidiol and less than 0.25mg of THCSubject t...

Cannabis-based medicine supplier Althea Group (AGH) records growth across most key metrics in its two arms of business for the 2022 financial yearThe company grew its revenue by 77.8 per cent to $20.52 million and improved its cash outflows...

Benchmark sags as Materials sector delivers even more tedious disappointment Coal miners hand back yesterday’s gains as investors tire of Chinese whispers Cannabis offers relief for investors and health stocks climb as well. The ASX has e...

ECS is selling its medicinal cannabis farm in Tasmania Crypto ATMs are now a thing in weed dispensaries in the US Zelira Therapeutics nabs regulatory approval in Germany for insomnia medication Ever fancied your own cannabis farm? Well, t...

The Althea Group Holdings Ltd (ASX: AGH) share price is up 5.25% today and up 21.25% over the past four days, as the nano-cap grabs the attention of ASX investors again. Althea is an ASX cannabis share. The company is focused on the manuf...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a sizeable decline. At the time of writing, the benchmark index is down 0.95% to 6,614.3 points. Four shares that are not letting that hold them b...

Cannabis company Althea Group (AGH) achieves a record quarter with $6.5 million in receipts for customers, a 130 per cent increase from the previous corresponding period This means that over FY22, AGH tabled $22 million in receipts from cu...

Over the past decade, opioid-induced deaths were more likely to be due to prescription drugs than illegal drugs As scientists discover new ways to use the plant’s medicinal compounds, cannabis is seen as a possible solution to the opioid c...

The Health Products Regulatory Authority approves Althea’s (AGH) CBD12:THC10 product to be used as prescription and supply in Ireland The approval marks Althea’s entry into the Irish medicinal cannabis market, and the first stop of its pla...

The Market Herald brings together several cannabis industry insiders to discuss the market Industry experts discuss the changing nature of the regulatory framework in various jurisdictions, and the growing science-based sophistication of c...

Althea Group (AGH) sees its best first-half result to date with $9.4 million in revenue reported, an 84 per cent increase compared to this time last year The medicinal cannabis company saw cash receipts total $9.9 million, a 67 per cent in...

At the time of writing, the ASX 200 Health Index (XHJ) is down by 1.10%, while the benchmark ASX 200 has fallen by 2.15%. It’s all about earnings today for ASX health stocks. Here’s a highlight of where they stand in the first half.   Round...